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Summary A retrospective cost-minimisation analysis was conducted comparing
novel chemotherapies for the treatment of chemo-naive patients with locally ad-
vanced, recurrent, and/or metastatic non-small cell lung cancer (NSCLC). Resource
use information was obtained from a Phase III randomised trial investigating the
efficacy and toxicity of gemcitabine/cisplatin (Gem/Cis), paclitaxel/carboplatin
(Pac/Carbo) and vinorelbine/cisplatin (Vin/Cis) combination regimens in 612Non-small cell lung
cancer;
Cost-minimisation;
Pharmacoeconomics
patients with advanced NSCLC. Since there were no statistically significant
differences between the three treatments in terms of progression-free or overall
survival in this trial, a cost-minimisation analysis was considered to be the
appropriate type of econom
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healthcare provider in Italy. Medical resource use was obtained from the clinical trial
database, from which mean cost streams were calculated for each treatment group.
The mean total treatment costs per patient were D 8094, D 11,203 and D 9320 for
the Gem/Cis, Pac/Carbo and Vin/Cis regimens, respectively. Based on resource con-
sumption in a clinical trial, Gem/Cis had the lowest overall mean costs of the three
chemotherapy regimens. Gem/Cis therefore has the potential to save costs in the
treatment of advanced NSCLC in Italy.
td.© 2005 Elsevier Ireland L
1. Introduction
Lung cancer remains the leading cause of cancer-
related death in Europe and North America, ac-
counting for nearly 30% of all cancer deaths [1].
Approximately 80% of all lung cancers are non-small
cell lung cancer (NSCLC), and more than 70% of pa-
tients with NSCLC present with locally advanced or
metastatic disease [2,3]. The prognosis for patients
with NSCLC remains poor: approximately 80% of pa-
tients die within 1 year of diagnosis, and the 5-year
survival rate is estimated at 14% in the USA and 8%
in Europe [4].
Currently, cisplatin-based regimens are consid-
ered the standard treatment for advanced NSCLC,
but the proportion of patients with advanced NSCLC
receiving chemotherapy varies widely across coun-
tries [5]. Chemotherapy prolongs survival and palli-
ates tumour-related symptoms [6,7], and has been
shown to be cost-effective [1].
New chemotherapeutic agents such as gem-
citabine, paclitaxel and vinorelbine have been
extensively tested in chemo-naive patients with
NSCLC, and randomised clinical trials have demon-
strated the activity of these new agents alone
or in combination with platinum derivatives for
the treatment of locally advanced and metastatic
NSCLC [8—16]. However, comparative studies have
failed to demonstrate the superiority of any one
of these so-called third-generation agents over the
others in terms of improved tumour response rate
or survival, although they do have different toxicity
profiles [3,8,9,17].
Given the similarity in the effectiveness of com-
bination chemotherapy regimens, decisions regard-
ing treatment for advanced NSCLC should take
into account the toxicity profiles, convenience and
costs. Healthcare utilisation data are beginning
to be collected prospectively during clinical tri-
als of chemotherapeutic regimens so that economic
analyses can be performed.Gemcitabine has already undergone extensive
economic evaluation, and been shown to be
cost-effective when used alone or in combina-
tion with cisplatin for treating advanced NSCLCAll rights reserved.
[5,18]. The aim of the present study was to
compare the mean costs of three chemother-
apy regimens — gemcitabine/cisplatin (Gem/Cis),
paclitaxel/carboplatin (Pac/Carbo) and vinorel-
bine/cisplatin (Vin/Cis) — in the treatment of
chemotherapy-naive patients with locally ad-
vanced, recurrent and/or metastatic NSCLC in Italy,
using resource utilisation data from a phase III ran-
domised clinical trial [9].
2. Methods
2.1. Patients and treatments
Resource utilisation data for the economic analy-
sis were collected prospectively during a phase III
randomised trial conducted in 41 centres in Italy,
which compared Gem/Cis, Pac/Carbo and Vin/Cis
in 612 chemotherapy-naive patients with locally
advanced (stage IIIB) and/or metastatic (stage IV)
NSCLC [9]. The median age of the patients was 63
years, approximately 78% were male, the majority
(92%) had Eastern Cooperative Performance Group
(ECOG) performance status 0—1, and 81% had stage
IV disease.
Of the 612 patients enrolled, 607 were ran-
domised to receive either Gem/Cis (n = 205),
Pac/Carbo (n = 201) or Vin/Cis (n = 201). The doses
and treatment schedules are summarised in Table 1.
Total drug dose was based on a mean body surface
area of 1.8m2 per patient. Patients who reached
stable disease received a maximum of six cycles of
therapy, whereas patients who demonstrated an ob-
jective response (complete or partial) could receive
up to eight cycles. Dose adjustments within a cycle
were made on the basis of haematological and non-
haematological toxicities as specified in the proto-
col [9].
The primary endpoint of the trial was overall re-
sponse rate, and the study was sufficiently powered
to detect a 15% difference in the overall response
rate between the Gem/Cis or Pac/Carbo arms and
the Vin/Cis arm. Time to disease progression and
overall survival were secondary endpoints.
Cost-minimisation analysis comparing gemcitabine/cisp
Table 1 Dosage and treatment schedules for the
chemotherapy regimens
Gem/Cis (n = 205) 21-day cycle
Gemcitabine: 1250mg/m2, two
doses per cycle (days 1 and 8)
Cisplatin: 75mg/m2, one dose
per cycle (day 2)
Mean cycles per patient = 4.02
Pac/Carbo (n = 201) 21-day cycle
Paclitaxel: 225mg/m2, one
dose per cycle (day 1)
Carboplatin: 400mg/m2 (AUC
6mg/mL/min Calvert’s
formula), one dose per cycle
(day 1)
Mean cycles per patient = 4.23
Vin/Cis (n = 201) 28-day cycle
Vinorelbine: 25mg/m2, four
doses per cycle (days 1, 8, 15
and 22)
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aCisplatin: 100mg/m , one dose
per cycle (day 1)
Mean cycles per patient = 3.25
.2. Treatment-related costs
he economic analysis was based on the intention-
o-treat population in the clinical trial. Direct
ealthcare costs were identified for each regimen,
sing the following categories: (1) chemotherapy
cquisition costs (third-generation agent and
latinum agent); (2) chemotherapy administra-
ion costs; (3) hospitalisation costs associated
ith adverse events; (4) costs of other medical
esources (e.g. radiotherapy, blood transfusions,
on-protocoled laboratory blood tests, concomi-
ant medications).
Chemotherapy acquisition costs were deter-
ined by multiplying the expected chemotherapy
ost per cycle by the mean number of cycles admin-
stered. The protocol-specified chemotherapy dose
as used for this calculation. Chemotherapy ad-
inistration costs per patient were determined by
ultiplying the expected number of administration
ays by the unit cost per drug administration day
all chemotherapy administrations were assumed
o be outpatient). The number of administration
ays was calculated by multiplying the number of
dministration days per cycle by the mean number
f cycles per patient.
The costs of hospitalisations due to adverse
vents were determined according to the propor-
ions of patients suffering an event in the clinical
rial, and the proportion of those patients who
ere then hospitalised for treatment of that event.
he hospitalisation cost per patient was calculated
p
d
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s follows:
C =
∑
PAE × PH × C
here HC is the mean hospitalisation cost, PAE the
robability of suffering each adverse event, PH the
robability of being hospitalised for that event,
nd C the unit cost of a hospitalised episode;
∑
epresents the fact that costs are summed across
ll adverse events reported in the clinical trial.
Hospitalisation costs associated with adverse
vents were calculated for grade 3/4 febrile neu-
ropenia, thrombocytopenia, anaemia, vomiting,
eutropenia, renal failure, and grade 2/3 neuropa-
hy. The probability of being hospitalised for one
f these events was 100%, with the exception of
rade 3/4 thrombocytopenia (9%). These probabil-
ties were derived from consultation with clinical
xperts and study of the trial datasets.
Finally, the costs of other medical resources
radiotherapy, blood transfusions, non-protocoled
aboratory blood tests, concomitant medications)
ere determined by multiplying the expected cost
er patient by the proportion of patients requiring
he intervention. Since data on radiotherapy use
ere not available from the trial, the percentage of
atients requiring radiotherapy was assumed to be
he same for each treatment group and was based
n that reported by Comella et al. [10] for Gem/Cis
23.33%). All medications used concomitantly with
hemotherapy in the clinical trial were grouped ac-
ording to chemical/therapeutic class, and a repre-
entative drug and corresponding defined daily dose
or each category was found. Calculations of days
f therapy in each category were based on prod-
ct information, prescriptive information provided
n the trial protocol and data drawn from the trial
ecords detailing the type and duration of concomi-
ant medication therapy for each patient.
Protocol-driven laboratory tests were excluded
rom the analysis. The per-patient cost of other
aboratory tests was calculated by multiplying the
robability of requiring tests by the mean number
f tests by the mean cost of a test. The mean cost of
laboratory test was the sum of the cost of blood
ampling plus the mean cost of different types of
aboratory tests administered in the trial (weighted
y frequency). For costing blood transfusions, both
acked red blood cell and platelet outpatient trans-
usions were counted.
Resource use was collected from the clinical trial
hen available. When resource use data were not
vailable from the trial, data were derived from
roduct information or other published literature.
Unit costs of medical resources in Italy were
erived from official published sources, including
EDERFARMA, May 2003 [19], the Italian Ministry of
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Health (Ministero della Sanita`) [20] and published
literature [21—23]. All unit costs are expressed in
2003 Euros (D ).
The mean total treatment cost per patient for
each regimen was calculated as the cost of the
stream of resources utilised across all patients ran-
domised to treatment in that arm.
2.3. Cost-minimisation analysis
The cost-minimisation analysis was based on the
clinical effectiveness results reported by Scagliotti
et al. [9] and the cost estimates derived in this
study using the methods described above.
One-way sensitivity analyses were performed
to quantify the effects of various cost drivers in
the analysis. All resource unit costs, except study
medications, were varied in both directions by
10%, and the associated mean costs per patient
were recorded. Similar sensitivity analyses were
performed for hospitalisation rates: costs and cost-
effectiveness were estimated in a scenario where
the rates of hospitalisation were 9% (the base-case
assumption for thrombocytopenic episodes) for all
types of adverse events. Costs were also estimated
in the scenario where 100% of thrombocytopenic
episodes were hospitalised. Finally, the sensitivity
analysis looked at a practical adjustment to the
dosing regimen of Gem/Cis in which cisplatin is
given together with gemcitabine on the first day of
a cycle.
3. Results3.1. Clinical outcomes
The efficacy and safety results of the clinical trial
have been published in detail elsewhere [9], but
3
T
m
Table 2 Clinical outcomes for each treatment group [9]
Gem/Cis
Response rates (% of patients)
Complete response 0
Partial response 30
Stable disease 40
Progressive disease 18
Not determinable 13
Overall response rate (% of patients (95% CI)) 30 (24—3
Survival
Median (months (95% CI)) 9.8 (8.6—
1-year (% surviving) 37
Median time to progression (months (95% CI)) 5.3 (4.4—
CI: confidence interval.S. Novello et al.
he relevant clinical outcomes are summarised
n Table 2. Median survival times (range 9.5—10
onths), overall response rates (range 30—32%) and
edian time to progression (range 4.6—5.5 months)
ere comparable in all three treatment groups. The
ack of significant differences confirms the applica-
ility of our cost-minimisation analysis.
.2. Treatment-related costs
he medical resource utilisation and unit costs
ased on the clinical trial and other published data
re listed in Table 3.
Patients treated with Gem/Cis had lower total
reatment costs (D 8094) than those treated with
ac/Carbo (D 11,203) or Vin/Cis (D 9320) (Fig. 1).
hemotherapy acquisition was a major cost factor
cross all regimens, ranging from D 1461 for Vin/Cis
o D 6615 for Pac/Carbo. The cost of hospitalisation
or adverse events was greatest in patients treated
ith Vin/Cis (D 4537), as were the costs of other
edical resources (D 2493).
The cost difference between the Gem/Cis and
ac/Carbo regimens (D 3109 per patient) was
ainly due to the much higher acquisition cost of
hemotherapy for the Pac/Carbo regimen, despite
he lower costs for drug administration and other
edical resources (Fig. 2a). The mean cost sav-
ng associated with Gem/Cis compared with Vin/Cis
as D 1226 per patient. The cost difference was pri-
arily due to the lower costs of hospitalisations as-
ociated with Gem/Cis, despite the higher cost of
hemotherapy acquisition (Fig. 2b)..3. Sensitivity analysis
he results of the various scenarios confirm the
ain findings of the cost-minimisation analysis
(n = 205) Pac/Carbo (n = 201) Vin/Cis (n = 201)
0.5 0.5
31 30
37 31
18 17
14 23
7) 32 (25—38) 30 (24—36)
11.2) 10.0 (9.0—12.5) 9.5 (8.3—11.0)
43 37
6.3) 5.5 (4.6—6.4) 4.6 (3.9—5.6)
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Table 3 Medical resource utilisation for each treatment group and unit costs
Medical resource Gem/Cis Pac/Carbo Vin/Cis Unit cost (D )
Drug administration (administration days per patient)
Outpatient 12.1 4.2 13.0 63.72
Inpatient 0 0 0 389.67
Hospitalisations (% patients)
Febrile neutropenia 0.5 1.0 3.0 2910.23
Thrombocytopenia 3.3 0.7 0.05 4790.65
Vomiting 6.6 0.5 12.6 2492.00
Neuropathy 4.0 29.8 7.0 3253.00
Anaemia 17.7 6.1 19.2 3393.64
Neutropenia 38.1 50.3 64.6 2910.23
Renal failure 0.5 0 5.0 27,481.17a
Other medical resources
Radiotherapy (% patients) 23.3 23.3 23.3 2845.00
Packed red blood cell transfusion
(% patients)
10.7 4.5 13.4 103.25
Platelet transfusion (% patients) 2.4 0 0 21.24
Laboratory tests (% patients) 22.0 5.5 19.4
Average no. of tests performed per patient 2.9 3.8 3.1 4.02
Concomitant medications (units per patient)
Dexamethasone 38.6 14.0 48.5 0.07
Ranitidine 5.9 7.6 8.8 3.38
Ondansetron 44.2 31.1 43.8 14.75
Furosemide 2.0 4.2 2.1 0.06
Pheniramine maleate 12.4 27.0 6.2 0.31
Ciprofloxacin 5.1 3.7 4.7 2.93
Filgrastim 0.6 1.4 2.3 141.77
Erythropoietin 3.3 1.0 3.8 180.66
Tramadol 10.4 4.3 6.0 0.76
Ketorolac trometamol 12.9 6.5 7.5 1.04
Heparin 4.2 3.7 9.4 10.9
Betamethasone phosphate 22.9 22.2 5.1 0.09
Chemotherapy
Platinum agent (vials required per patient)
450mg vials 0 4.23 0 195.82
50mg vials 8.04 25.38 9.75 18.02 (Cis);
21.59 (Carbo)
25mg vials 4.02 0 3.25 9.41
10mg vials 4.02 0 3.25 6.44
Novel agent (vials required per patient)
1000mg vials 16.08 0 0 137.75
200mg vials 16.08 0 0 28.58
100mg vials 0 16.92 0 276.77
50mg vials 0 0 13.0 94.92
reatm
(
i
q
t
t
p
t
t
D
t
c
f30mg vials 0
a Dialysis cost per 9.73 months (mean survival time across t
Table 4). It is clear that the major cost driver
n the treatment of NSCLC is chemotherapy ac-
uisition costs and that other resource use in the
rial generally did not have a significant impact on
he conclusions. The largest effect on costs was
roduced by varying the hospitalisation rates for
he adverse events: total treatment costs per pa-
ient varied from D 6134 to D 9688 (Gem/Cis), from
e
p
p
t4.23 0 131.34
ent arms).
8765 to D 11,538 (Pac/Carbo), and from D 5197
o D 9341 (Vin/Cis). Changes to hospitalisation
osts also affected costs for Vin/Cis, which ranged
rom D 8866 to D 9773 per patient, but had little
ffect on Pac/Carbo costs (D 10,932 to D 11,475
er patient) or Gem/Cis costs (D 7862 to D 8326 per
atient). Similarly, changes in the costs of concomi-
ant medications had a clear impact on Pac/Carbo
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Fig. 1 Mean treatment-related costs per patient for
each treatment group.
Fig. 2 Differences in cost (D ) per patient between (a)
Gem/Cis and Pac/Carbo and (b) Gem/Cis and Vin/Cis
treatment groups, by medical resource.
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Table 4 Sensitivity analysis of mean total treatment costs
Sensitivity analysis Mean total
treatment costs (
Gem/Cis
Base case 8094
Hospitalisation rates (all 100%) 9688
Hospitalisation rates (all 9%) 6134
Hospitalisation costs +10% 8326
Hospitalisation costs −10% 7862
Cisplatin administered on day 1 of cycle 7838
Drug admin costs +10% 8171
Drug admin costs −10% 8017
Concomitant meds costs +10% 8527
Concomitant meds costs −10% 7661
Other resource costs +10% 8162
Other resource costs −10% 8026S. Novello et al.
esults (D 10,448 to D 11,958 per patient) but little
ffect on the other treatment groups.
. Discussion
ost-minimisation analysis compares the costs of
ifferent treatment options under the assumption
hat the clinical outcome of the compared treat-
ents or interventions is equivalent. It therefore
ocuses on comparing the cost of the treatment
nly, not the outcomes. Using this form of analysis,
he treatment of choice is the option with the low-
st overall cost. In the randomised trial in advanced
SCLC patients by Scagliotti et al. [9], there were
o statistically significant differences between the
hree treatments (Gem/Cis, Pac/Carbo, Vin/Cis)
n terms of progression-free or overall survival.
herefore, cost-minimisation was the appropriate
orm of economic evaluation. However, it should
e noted that in the trial performed by Scagliotti et
l. [9] there were some statistically significant dif-
erences between regimens with regard to quality-
f-life endpoints. These differences raise the pos-
ibility of performing a cost-utility analysis using
he study data. However, a cost-utility analysis was
onsidered beyond the scope of the current anal-
sis and was not performed as part of the present
tudy.
The results of this retrospective economic ana-
ysis show that Gem/Cis was associated with lower
otal treatment costs than Pac/Carbo and Vin/Cis in
he treatment of advanced NSCLC in Italy. Although
he cost of chemotherapy was a major driver of the
verall treatment costs for these platinum-based
ombination regimens, the costs of hospitalisations
nd other medical resources were also important
for the three treatment groups
D )
Mean and incremental total treatment costs (D )
Pac/Carbo (difference
from Gem/Cis)
Vin/Cis (difference
from Gem/Cis)
11,203 (+3109) 9320 (+1226)
11,538 (+1850) 9341 (−347)
8765 (+2631) 5197 (−937)
11,475 (+3149) 9773 (+1447)
10,932 (+3070) 8866 (+1004)
11,203 (+3365) 9320 (+1482)
11,230 (+3059) 9403 (+1232)
11,176 (+3159) 9237 (+1220)
11,958 (+3431) 9647 (+1120)
10,448 (+2787) 8992 (+1331)
11,270 (+3108) 9388 (+1226)
11,136 (+3110) 9252 (+1226)
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fost-minimisation analysis comparing gemcitabine/
actors. The chemotherapy acquisition costs were
ighest for Pac/Carbo and accounted for 59%
f the total costs per patient. In comparison,
hemotherapy acquisition accounted for 36% of the
otal costs of the Gem/Cis regimen and for only
6% of the total costs of the Vin/Cis regimen.
Our findings agree with previous economic evalu-
tions in advanced NSCLC. In a recent retrospec-
ive cost-minimisation analysis of two randomised
rials [8,10], Schiller et al. [24] found that Gem/Cis
as associated with lower treatment-related
osts than Vin/Cis, Pac/Cis or Pac/Carbo in five
uropean countries (France, Germany, Italy, Spain,
K). Another retrospective analysis using published
linical trial data showed that Gem/Cis was
ssociated with lower total treatment costs than
in/Cis or Pac/Carbo [18]. In the latter analysis,
he reduced costs with Gem/Cis were due to lower
hemotherapy administration costs compared with
in/Cis and lower chemotherapy drug costs com-
ared with Pac/Carbo.
In our analysis, all chemotherapy was adminis-
ered on an outpatient basis; the chemotherapy
dministration costs were comparable between
he Gem/Cis and Vin/Cis regimens and lower for
he Pac/Carbo regimen. The main cost difference
etween the two cisplatin-based regimens was due
o the lower costs for hospitalisation associated
ith adverse events in the Gem/Cis group. Previous
tudies have also indicated that the higher drug
cquisition costs of gemcitabine regimens can be
ffset by a decrease in hospitalisation costs [25].
In our analysis, Pac/Carbo was more expensive in
erms of total resource costs than either Gem/Cis
r Vin/Cis. This is consistent with a recent eco-
omic analysis of the large Southwest Oncology
roup (SWOG) trial, which reported that Pac/Carbo
as significantly more expensive than Vin/Cis in pa-
ients with advanced NSCLC [26]. The major cost
ifference was due to the high acquisition costs
f chemotherapy drugs in the Pac/Carbo regimen,
hich were not offset by lower costs elsewhere
such as for hospitalisations due to adverse events).
chiller et al. [24] also found that the main cost
ifference between Gem/Cis and Pac/Carbo was
ue to the higher acquisition costs of chemother-
py associated with Pac/Carbo in all five Euro-
ean countries studied. Indeed, Ramsey et al. [26]
arned that widespread use of Pac/Carbo rather
han Vin/Cis would substantially increase national
xpenditures for the treatment of advanced lung
ancer.
Although the chemotherapy acquisition costs
ere much lower for the Vin/Cis regimen than the
em/Cis and Pac/Carbo regimens, the costs for out-
atient administration of the chemotherapy were
b
i
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ighest for this treatment group. This agrees with
oth economic analyses based on the clinical trial
y Comella et al. [10], which found that Gem/Cis
as associated with a lower total cost relative to
in/Cis due to the higher administration costs of
he latter regimen [18,24]. The analysis by Lees et
l. [18] made assumptions that the use of resources
uch as hospitalisation, transfusion and concomi-
ant medication would be identical in the two treat-
ent groups. These assumptions may not be valid,
owever, since our analysis based on the clinical
rial published by Scagliotti et al. [9] found that
in/Cis treatment incurred higher costs associated
ith hospitalisation and other medical resources
han either Gem/Cis or Pac/Carbo. In addition,
chiller et al. [24] found that hospitalisations pro-
ided the largest cost saving between the Gem/Cis
nd Vin/Cis regimens in France, Germany and Italy.
oreover, although not a consistent finding [27],
ome previous studies have found that Vin/Cis regi-
ens are associated with higher toxicity and worse
olerability than Gem/Cis [10] or Pac/Carbo [17].
t must be noted that the chemotherapeutic regi-
ens used in different clinical studies often vary in
erms of dosages or mean cycle length. Both fac-
ors can have a large impact on overall treatment
osts, making it difficult to compare cost results
cross studies.
The present study has some inevitable limita-
ions. First, the resource utilisation data on which
he analysis is based were to a certain extent
rotocol-driven. Although this is a recommended
ethod for pharmacoeconomic assessment [28,29],
he resource use may not accurately reflect real
linical practice. The analysis excluded protocol-
riven costs where possible and focused on the
ain cost components. However, as patients in
linical trials are likely to be closely monitored and
bserved, the resource use is probably overesti-
ated in this analysis. Second, direct non-medical
osts (such as those associated with domestic help
nd home nursing and costs incurred by patients
ravelling to the clinic/hospital) and the indirect
osts of lost productivity were not considered in
he analysis since the study perspective was that of
he national healthcare provider and it was there-
ore considered inappropriate to include these
osts.
In contrast to many previous economic eval-
ations, the present analysis used outcome and
esource utilisation data collected prospectively
rom the same source, thereby limiting selection
ias. However, not all the resources documented
n the clinical trial database were costed. As every
rug for each patient was specifically documented,
e would have had to look up the cost for hundreds
[[
[
[
[
[
[
[
[
[
[386
of individual drugs, many of which are similar in
price. For the sake of simplicity, only the most
frequently used concomitant medication or very
expensive medication was costed and included in
the analysis. Second-line chemotherapy and radio-
therapy were not costed in the present analysis,
although they were documented by Scagliotti et al.
[9]. The requirements for second-line chemother-
apy or radiotherapy appeared to be fairly well
balanced between treatment groups [9], but no
statistical analysis was performed on these data.
It is possible, therefore, that the costs relating
to second-line chemotherapy or radiotherapy may
have influenced the results of the present analysis
had they been included.
5. Conclusion
This retrospective cost-minimisation analysis has
shown that Gem/Cis is associated with lower mean
total costs than Pac/Carbo or Vin/Cis when used as
first-line treatment for NSCLC. For decision makers
with a limited budget, the Gem/Cis regimen there-
fore represents an efficient use of resources for pa-
tients with advanced NSCLC in Italy.
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